After TREGZI Approval, Immune Balance in Blood Cancer Transplantation Becomes a Treatment Focus

For many patients with hematologic malignancies, allogeneic hematopoietic stem cell transplantation is both a treatment that may bring long-term control and the starting point of an immune storm. After new bone marrow and immune cells enter the patient's body, they may attack residual cancer cells, but they may also view the patient's own tissues as enemies. The U.S. FDA's approval of TREGZI pushes this long-standing dilemma into a new therapeutic logic: preventing complications does not rely only on suppressing immune responses after the fact; it can also begin with designing the composition of the transplanted cells.

Orca Bio announced that TREGZI has been approved by the FDA for adult patients with hematologic malignancies who receive matched-donor hematopoietic stem cell transplantation and myeloablative conditioning, to improve chronic graft-versus-host disease-free, event-free survival. The prescribing information defines it as an allogeneic regulatory T-cell immunotherapy containing hematopoietic stem and progenitor cells, purified regulatory T cells, and conventional T cells.

The key to this therapy is not a single cell type, but the rearrangement of the transplant package. According to the labeling, TREGZI consists of multiple infusion bags containing HSPC, Treg, Tcon, and Tcon diluent; HSPC and Treg are infused on Day 0, while Tcon is administered from Day +2 to Day +3. This timing reflects an immunologic hypothesis: allowing regulatory T cells to help establish a tolerogenic environment first, and then introducing conventional T cells, may preserve the graft-versus-leukemia effect while reducing chronic GVHD.

The approval was based mainly on the randomized, multicenter Phase 3 Precision-T trial, which enrolled 187 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia. Data released by the company showed that at 12 months, the chronic GVHD-free, event-free survival rate was 78% in the TREGZI group and 38% in the standard allogeneic transplant group; the incidence of chronic GVHD was 13% and 44%, respectively. The clinical studies section of the prescribing information also lists the Precision-T trial number NCT05316701 and reports chronic GVHD-free, event-free survival event rates of 15.1% versus 46.8%, with a hazard ratio of 0.26.

These numbers show a clear signal, but they also need to be read within the realities of transplant medicine. TREGZI is a personalized product made from matched-donor living cells, and its indicated population is limited to adult hematologic malignancy patients in the setting of matched-donor transplantation and myeloablative conditioning; for mismatched donors, reduced-intensity conditioning, pediatric patients, or other transplant conditions, publicly available data cannot be directly extrapolated. Cell manufacturing, logistics timelines, transplant center experience, and access to payment will also affect whether it can truly enter routine clinical practice.

Chronic GVHD often emerges gradually months after transplantation and may affect the skin, eyes, mouth, lungs, liver, and gastrointestinal tract, leaving patients who have already passed the peak of cancer treatment dependent on immunosuppression over the long term. If TREGZI sustains the trial results in the real world, its significance would not only be reducing the rate of one complication, but potentially changing the balance among post-transplant quality of life, infection risk, and the burden of follow-up care.

**Background Context**

In recent years, news about cell therapy has largely focused on treatments such as CAR-T that directly attack tumors; TREGZI's positioning is closer to immune ecosystem engineering, with the goal of making immune reconstitution after transplantation less likely to spin out of control. This also makes its criteria for success more complex: efficacy is measured not only by cancer relapse, but also by whether GVHD, infections, long-term immune function, and quality of survival can benefit together. FDA approval opens the door to clinical use, but the real answer will still take shape gradually across more patients, more transplant centers, and longer follow-up.